- Title: Subtitle
- Cardiac safety analysis of trabectedin (T) vs. dacarbazine (D) in patients (Pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior anthracycline chemotherapy
- Creators
- Scott Schuetze - University of Michigan–Ann ArborShreyaskumar Patel - The University of Texas MD Anderson Cancer CenterMargaret von Mehren - Temple University Health SystemChristopher W. Ryan - Oregon Health & Science UniversityMohammed M. Milhem - University of IowaBrian Andrew Van Tine - Washington University in St. LouisSharon Anne McCarthyGeorge C. Wang - Washington University in St. LouisLoreta MarquezTrilok V. ParekhRoland Elmar KnoblauchGeorge D. Demetri - Dana-Farber Cancer Institute
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.34(15_suppl), pp.11060-11060
- DOI
- 10.1200/JCO.2016.34.15_suppl.11060
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2016
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363181602771
Abstract
Cardiac safety analysis of trabectedin (T) vs. dacarbazine (D) in patients (Pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior anthracycline chemotherapy
Journal of clinical oncology, Vol.34(15_suppl), pp.11060-11060
05/20/2016
DOI: 10.1200/JCO.2016.34.15_suppl.11060
Details
Metrics
11 Record Views